Advanced Technology for Assessing HIV Susceptibility to Entry Inhibitors

PhenoSense Entry provides unmatched clinical utility to help healthcare providers determine whether to begin or discontinue Fuzeon® (enfuvirtide).

Entry Inibitor Challenges

• Fuzeon can be an effective part of an antiretroviral regimen, but clinical studies have shown a wide variation in baseline susceptibility to Fuzeon among HIV patients.
• HIV can rapidly become resistant to Fuzeon, even after brief exposure.
• If a failing regimen includes Fuzeon, healthcare providers need a complete picture of the drug resistance to determine which components to change, as Fuzeon may still be effective.

Meeting the Need

• Together with PhenoSenseGT® (combination phenotype/genotype drug resistance test), PhenoSense Entry provides the most complete picture of resistance to antiretroviral medications.
• PhenoSense Entry is the only commercially available phenotypic test for measuring susceptibility to entry inhibitors.

When to Use PhenoSense Entry

• Before adding Fuzeon to a patient's regimen – to assess its likely effectiveness.
• Before changing a regimen that includes Fuzeon – to determine how effective each component is.

Why Choose PhenoSense Entry

• PhenoSense Entry assesses resistance to Fuzeon, which interacts with glycoprotein gp41 of the HIV envelope.
• Genotype testing of gp41 is insufficient to address variability in the HIV envelope and the wide range of fold changes observed with similar mutational patterns.
• Unique test offered by the leading provider of phenotypic resistance tests, Monogram Biosciences®

PhenoSense Entry Features

• Phenotypic susceptibility test measuring resistance to enfuvirtide
• Turn around time is 2 weeks
• HIV RNA requirements is > 1,000 copies/mL
• The plasma volume required is 3 mL